CASI Pharmaceuticals (OTC: CASIF) controller reports multiple stock option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
CASI Pharmaceuticals, Inc. filed an initial ownership report showing that Global Controller Qian Kun holds several stock option awards on the company’s ordinary shares. The options cover different blocks of shares with exercise prices of $1.93, $2.67, and $5.78 per share and expire between 2032 and 2034. Footnotes state that the options are fully vested and exercisable as of the reporting date, and that some are performance based and become exercisable upon achievement of a performance target.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Qian Kun
Role
Global Controller
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 8,000 shares (Direct)
Footnotes (1)
- The options are fully vested and exercisable as of the date of this form. Performance based options exercisable upon achievement of performance target.
Key Figures
Option grant underlying shares: 8,000 shares
Option grant underlying shares: 13,333 shares
Option grant underlying shares: 6,667 shares
+3 more
6 metrics
Option grant underlying shares
8,000 shares
Ordinary shares at $1.93 exercise price expiring March 20, 2032
Option grant underlying shares
13,333 shares
Ordinary shares at $1.93 exercise price expiring May 12, 2033
Option grant underlying shares
6,667 shares
Ordinary shares at $1.93 exercise price expiring May 12, 2033
Option grant underlying shares
3,000 shares
Ordinary shares at $2.67 exercise price expiring June 18, 2034
Large option grant underlying shares
30,000 shares
Ordinary shares at $5.78 exercise price expiring November 6, 2034
Additional option grant underlying shares
5,000 shares
Ordinary shares at $5.78 exercise price expiring November 6, 2034
Key Terms
Option (right to buy), Global Controller, Performance based options, exercise price, +1 more
5 terms
Option (right to buy) financial
"security_title: "Option (right to buy)""
Global Controller financial
"officer_title: "Global Controller""
Performance based options financial
"Performance based options exercisable upon achievement of performance target."
exercise price financial
"conversion_or_exercise_price: "1.9300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2034-11-06T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What does the CASI (CASIF) Form 3 filing for Qian Kun show?
The Form 3 shows Global Controller Qian Kun’s existing stock option holdings in CASI Pharmaceuticals. It lists multiple options on ordinary shares with exercise prices of $1.93, $2.67, and $5.78 and expirations between 2032 and 2034.
What are the exercise prices of Qian Kun’s CASI stock options?
The options disclosed carry exercise prices of $1.93, $2.67, and $5.78 per ordinary share. Each exercise price applies to specific grants, which also have different expiration dates extending from 2032 through 2034.
When do Qian Kun’s CASI Pharmaceuticals options expire?
The disclosed options expire on several future dates between 2032 and 2034. Specific expirations include March 20, 2032, May 12, 2033, June 18, 2034, and November 6, 2034, depending on the individual option grant.
Are Qian Kun’s CASI stock options already vested and exercisable?
A footnote states that the options are fully vested and exercisable as of the Form 3 date. Another footnote explains that certain performance based options become exercisable only upon achievement of a specified performance target, adding a performance condition to those particular grants.
Does the CASI Form 3 show any recent insider buying or selling by Qian Kun?
The Form 3 is an initial ownership statement and lists existing option holdings rather than new market trades. The transaction summary shows no recorded buy or sell transactions, only holding entries for previously granted stock options on CASI ordinary shares.